The only FDA-approved prescription eyedrop
proven to raise upper eyelids in adults with acquired
blepharoptosis (low-lying lids)



• Alpha-adrenergic agonists as a class may impact blood pressure. Advise Upneeq patients with
cardiovascular disease, orthostatic hypotension, and/or uncontrolled hypertension or hypotension to seek
medical care if their condition worsens.
• Use Upneeq with caution in patients with cerebral or coronary insufficiency or Sjögren’s syndrome. Advise
patients to seek medical care if signs and symptoms of potentiation of vascular insufficiency develop.
• Upneeq may increase the risk of angle closure glaucoma in patients with untreated narrow-angle
glaucoma. Advise patients to seek immediate medical care if signs and symptoms of acute narrow-angle
glaucoma develop.
• Patients should not touch the tip of the single patient-use container to their eye or to any surface, in order
to avoid eye injury or contamination of the solution.

Adverse reactions that occurred in 1-5% of subjects treated with Upneeq were punctate keratitis, conjunctival
hyperemia, dry eye, blurred vision, instillation site pain, eye irritation, and headache.

• Alpha-adrenergic agonists, as a class, may impact blood pressure. Caution in using drugs such as beta
blockers, anti-hypertensives, and/or cardiac glycosides is advised. Caution should also be exercised
in patients receiving alpha adrenergic receptor antagonists such as in the treatment
of cardiovascular disease, or benign prostatic hypertrophy.
• Caution is advised in patients taking monoamine oxidase inhibitors which
can affect the metabolism and uptake of circulating amines.